BIOBIO-RAD LABORATORIES, INC.
Laboratory Analytical Instruments
- Revenue
- $2.6B
- 0.7% YoY
- Operating margin
- 1.8%
- 83% YoY
- EBITDA
- $213M
- 49% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -0.4×
- −$77M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired70% of net incomeCash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear56% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear6% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | $2.8B | $2.7B | $2.6B | $2.6B | 0.7% |
| Operating income | $500M | $483M | $338M | $269M | $47M | 82% |
| Net income | $4.3B | −$3.6B | −$637M | −$1.8B | $760M | 141% |
| Operating cash flow | $669M | $194M | $375M | $455M | $532M | 17% |
| Capex | $134M | $113M | $157M | $166M | $158M | 4.8% |
| Stock-based comp | $51M | $61M | $61M | $62M | $58M | 6.9% |
| Buybacks | $50M | $216M | $429M | $204M | $296M | 45% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.